NCT06102928 2023-10-26
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Kunming Medical University
Phase NA Recruiting
Clinical Trials
1 trialsInterventional × Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor × aumolertinib × Clear all